Costs, regulations, foreign innovation are key issues for biosimilars: US Biocom panel
This article was originally published in SRA
Executive Summary
Uncertainty abounds in regard to biosimilars – whether and how companies should enter that line of business and how large the market will be when they get there – but a select few have immersed themselves in that realm, for better or worse.